Imatinib mesylate improves insulin sensitivity and glucose disposal rates in rats fed a high-fat diet

Clinical Science

Volumn 114, Issue 1-2, 2008, Pages 65-71

  Hägerkyist, Robert ^a   Jansson, Leif ^a   Welsh, Nils ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

Glucose disposal; High fat diet; Imatinib mesylate; Insulin sensitivity; Type 2 diabetes

Indexed keywords

IMATINIB; INSULIN; SODIUM CHLORIDE; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; FEEDING; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; GLUCOSE METABOLISM; HYPERINSULINEMIA; INSULIN SENSITIVITY; LIPID DIET; LOW FAT DIET; MALE; NONHUMAN; PRIORITY JOURNAL; PSOAS MUSCLE; RAT; SPRAGUE DAWLEY RAT; ANIMAL; BLOOD; BLOOD PRESSURE; DOSE RESPONSE; DRUG EFFECT; DRUG SCREENING; FAT INTAKE; HEMATOCRIT; HISTOLOGY; INSULIN RESISTANCE; METABOLISM; ORGAN SIZE; PANCREAS;

ANIMALS; BLOOD GLUCOSE; BLOOD PRESSURE; DIETARY FATS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; GLUCOSE CLAMP TECHNIQUE; HEMATOCRIT; INSULIN; INSULIN RESISTANCE; MALE; ORGAN SIZE; PANCREAS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 38349064869     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20070122     Document Type: Article

References (25)

1. Buchdunger, E., Zimmermann, J., Mett, H. et al. (1996) Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 56, 100-104
2. Okuda, K., Weisberg, E., Gilliland, D. G. and Griffin, J. D. (2001) ARG tyrosine kinase activity is inhibited by STI571. Blood 97, 2440-2448
3. O'Brien, S. G., Guilhot, F., Larson, R. A. et al. (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 348, 994-1004
4. Demetri, G. D., von Mehren, M., Blanke, C. D. et al. (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 347, 472-480
5. Veneri, D., Franchini, M. and Bonora, E. (2005) Imatinib and regression of type 2 diabetes. N. Engl. J. Med. 352, 1049-1050
6. Breccia, M., Muscaritoli, M., Aversa, Z., Mandelli, F. and Alimena, G. (2004) Imatinib mesylate may improve fasting blood glucose in diabetic Ph+ chronic myelogenous leukemia patients responsive to treatment. J. Clin. Oncol. 22, 4653-4655
7. Dingli, D., Wolf, R. C. and Vella, A. (2007) Imatinib and Type 2 diabetes. Endocr. Prac. 13, 126-130
8. Hamberg, P., de Jong, F. A., Bonnstra, J. G., van Doorn, J., Verweij, J. and Sleifer, S. (2006) Non-islet-cell tumor induced hypoglycemia in patients with advanced gastrointestinal stromal tumor possibly worsened by imatinib. J. Clin. Oncol. 24, e30-e31
9. Folli, F., Galimberti, G., Pastore, M. and Davalli, A. M. (2006) Paraneoplastic insulin resistance syndrome in advanced aggressive fibromatosis (desmoid tumor) treated by imatinib mesylate. Diabetes Care 29, 2178-2179
10. Hägerkvist, R., Sandler, S., Mokhtari, D. and Welsh, N. (2007) Amelioration of diabetes by imatinib mesylate (Gleevec): role of β-cell NF-κB activation and anti-apoptotic preconditioning. FASEB J. 21, 618-628
11. Hägerkvist, R., Makeeva, N. and Elliman, S., Welsh N. (2006) Imatinib mesylate (Gleevec) protects against streptozotocin-induced diabetes and islet cell death in vitro. Cell. Biol. Int. 30, 1013-1017
12. Schneider, J. G., Finck, B. N., Ren, J. et al. (2006) ATM-dependent suppression of stress signaling reduces vascular disease in metabolic syndrome. Cell Metab. 4, 377-389
13. Storlien, L. H., James, D. E., Burleigh, K. M., Chisholm, D. J. and Kraegen, E. W. (1986) Fat feeding causes widespread in vivo insulin resistance, decreased energy expenditure, and obesity in rats. Am. J. Physiol. 251, E576-E583
14. Jansson, L., Andersson, A., Bodin, B. and Källskog, Ö. (2007) Pancreatic islet blood flow during euglycaemic, hyperinsulinaemic clamp in anaesthetized rats. Acta Physiol. 189, 310-324
15. Holmäng, A., Mimura, K., Björntorp, P. and Lönnroth, P. (1997) Interstitial muscle insulin and glucose levels in normal and insulin-resistant Zucker rats. Diabetes 46, 1799-1804
16. cp rats. J. Appl. Physiol. 77, 534-541
17. Kolterman, O. G., Gray, R. S., Griffin, J. et al. (1981) Receptor and postreceptor defects contribute to the insulin resistance in noninsulin-dependent diabetes mellitus. J. Clin. Invest. 68, 957-969
18. Myllärniemi, M., Frösen, J., Calderón Ramirez, G., Buchdunger, E., Lemström, K. and Häyry, P. (1999) Selective tyrosine kinase inhibitor for the platelet-derived growth factor receptor in vitro inhibits smooth muscle cell proliferation after reinjury of arterial intima in vivo. Cardiovasc. Drugs Ther. 13, 159-168
19. Cohen, M. H., Williams, G., Johnson, J. R. et al. (2002) Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin. Cancer Res. 8, 935-942
20. Anand, K. J. (1986) The stress response to surgical trauma: from physiological basis to therapeutic implications. Prog. Food Nutr. Sci. 10, 67-132
21. Kaneto, H., Katakami, N., Kawamori, D. et al. (2007) Involvement of oxidative stress in the pathogenesis of diabetes. Antioxid. Redox Signaling 9, 355-366
22. Kharbanda, S., Pandey, P., Yamauchi, T. et al. (2000) Activation of MEK kinase 1 by the c-Abl protein tyrosine kinase in response to DNA damage. Mol. Cell. Biol. 20, 4979-4989
23. Loukinova, E., Ranganathan, S., Kuznetsov, S. et al. (2002) Platelet-derived growth factor (PDGF)-induced tyrosine phosphorylation of the low density lipoprotein receptor-related protein (LRP). Evidence for integrated co-receptor function between LRP and the PDGF. J. Biol. Chem. 277, 15499-15506
24. Gottardi, M., Manzato, E. and Gherlinzoni, F. (2006) Imatinib and hyperlipidemia, N. Engl. J. Med. 353, 2722-2723
25. Boucher, P., Gotthardt, M., Li, W. P., Anderson, R. G. and Herz, J. (2003) LRP: role in vascular wall integrity and protection from atherosclerosis. Science 300, 329-332